JP2007519659A5 - - Google Patents

Download PDF

Info

Publication number
JP2007519659A5
JP2007519659A5 JP2006550019A JP2006550019A JP2007519659A5 JP 2007519659 A5 JP2007519659 A5 JP 2007519659A5 JP 2006550019 A JP2006550019 A JP 2006550019A JP 2006550019 A JP2006550019 A JP 2006550019A JP 2007519659 A5 JP2007519659 A5 JP 2007519659A5
Authority
JP
Japan
Prior art keywords
imidazo
acetic acid
formula
drug
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006550019A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007519659A (ja
JP4996257B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2005/000475 external-priority patent/WO2005073234A2/en
Publication of JP2007519659A publication Critical patent/JP2007519659A/ja
Publication of JP2007519659A5 publication Critical patent/JP2007519659A5/ja
Application granted granted Critical
Publication of JP4996257B2 publication Critical patent/JP4996257B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006550019A 2004-01-31 2005-01-19 イミダゾ[1,2−c]ピリミジニル酢酸誘導体 Expired - Fee Related JP4996257B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04002144.6 2004-01-31
EP04002144 2004-01-31
PCT/EP2005/000475 WO2005073234A2 (en) 2004-01-31 2005-01-19 Imidazo[1,2-c]pyrimidinylacetic acid derivatives

Publications (3)

Publication Number Publication Date
JP2007519659A JP2007519659A (ja) 2007-07-19
JP2007519659A5 true JP2007519659A5 (https=) 2011-11-17
JP4996257B2 JP4996257B2 (ja) 2012-08-08

Family

ID=34814234

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006550019A Expired - Fee Related JP4996257B2 (ja) 2004-01-31 2005-01-19 イミダゾ[1,2−c]ピリミジニル酢酸誘導体

Country Status (23)

Country Link
US (1) US7750014B2 (https=)
EP (1) EP1718649B1 (https=)
JP (1) JP4996257B2 (https=)
KR (1) KR101207428B1 (https=)
CN (1) CN100584844C (https=)
AT (1) ATE433452T1 (https=)
AU (1) AU2005209381B2 (https=)
BR (1) BRPI0507123A (https=)
CA (1) CA2551778C (https=)
CY (1) CY1109274T1 (https=)
DE (1) DE602005014849D1 (https=)
DK (1) DK1718649T3 (https=)
ES (1) ES2326896T3 (https=)
IL (1) IL177083A (https=)
MX (1) MXPA06007674A (https=)
NO (1) NO20063878L (https=)
NZ (1) NZ548396A (https=)
PL (1) PL1718649T3 (https=)
PT (1) PT1718649E (https=)
RU (1) RU2373208C2 (https=)
SI (1) SI1718649T1 (https=)
WO (1) WO2005073234A2 (https=)
ZA (1) ZA200605387B (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2594280C (en) 2004-12-27 2013-04-23 Anja Fecher 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
ATE530523T1 (de) 2006-08-07 2011-11-15 Actelion Pharmaceuticals Ltd (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)- essigsäurederivate
CA2681311A1 (en) * 2007-04-13 2008-10-23 Novartis Ag Pyridazine-, pyridine- and pyrane-derivatives as gpbar1 agonisis
US8507005B2 (en) * 2007-06-21 2013-08-13 Actimis Pharmaceuticals, Inc. Particulates of a CRTH2 antagonist
BRPI0817318A2 (pt) 2007-09-25 2015-03-17 Actimis Pharmaceuticals Inc Composto, composição farmacêutica, e, método para tratar uma doença, ou uma condição, ou sintoma da mesma.
JP5524847B2 (ja) * 2007-09-25 2014-06-18 アクチミス ファーマシューティカルズ インコーポレーテッド Crth2アンタゴニストとしてのアルキルチオピリミジン
WO2009102893A2 (en) 2008-02-14 2009-08-20 Amira Pharmaceuticals, Inc. CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 receptors
US8426449B2 (en) 2008-04-02 2013-04-23 Panmira Pharmaceuticals, Llc Aminoalkylphenyl antagonists of prostaglandin D2 receptors
US8541419B2 (en) 2008-09-02 2013-09-24 Actimis Pharmaceuticals, Inc. Isotopically enriched pyrimidin-5-yl acetic acid derivatives as CRTH2 antagonists
US8383654B2 (en) 2008-11-17 2013-02-26 Panmira Pharmaceuticals, Llc Heterocyclic antagonists of prostaglandin D2 receptors
AR080703A1 (es) 2010-03-22 2012-05-02 Actelion Pharmaceuticals Ltd Derivados de 3-(heteroaril-amino)-1,2,3,4-tetrahidro-9h-carbazol, moduladores de receptores de prostaglandina d2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos alergicos o inmunitarios tales como asma.
CN102958914B (zh) 2010-07-05 2015-05-27 埃科特莱茵药品有限公司 1-苯基取代的杂环衍生物及其作为前列腺素d2受体调节剂的用途
EA201390060A1 (ru) 2010-07-09 2013-07-30 Байер Интеллектуэль Проперти Гмбх Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний
DE102011003315A1 (de) 2011-01-28 2012-08-02 Bayer Schering Pharma Aktiengesellschaft Annellierte Pyrimindine und Triazine und ihre Verwendung
DE102010031149A1 (de) 2010-07-09 2012-01-12 Bayer Schering Pharma Aktiengesellschaft Annellierte Pyrimidine und Triazine und ihre Verwendung
EP2627178B1 (en) 2010-10-11 2018-05-02 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as crth2 antagonists
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
DK2697223T3 (en) 2011-04-14 2016-09-05 Actelion Pharmaceuticals Ltd 7- (heteroaryl-amino) -6,7,8,9-tetrahydro-pyrido [1,2-a] indole-acetic acid derivatives and their use as prostaglandin D2 receptor
SG11201402796SA (en) 2011-12-16 2014-06-27 Atopix Therapeutics Ltd Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
TW201331179A (zh) 2011-12-21 2013-08-01 Actelion Pharmaceuticals Ltd 雜環衍生物及其作為前列腺素d2受體調節劑之用途
DE102012200360A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte Triazine und ihre Verwendung
DE102012200349A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte annellierte Pyrimidine und Triazine und ihre Verwendung
WO2013131923A1 (de) 2012-03-06 2013-09-12 Bayer Intellectual Property Gmbh Substituierte azabicyclen und ihre verwendung
CA2876808A1 (en) 2012-07-05 2014-01-09 Actelion Pharmaceuticals Ltd 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
PE20161177A1 (es) 2014-03-17 2016-11-18 Actelion Pharmaceuticals Ltd Derivados del acido acetico azaindol y su uso como moduladores del receptor de prostaglandina d2
WO2015140701A1 (en) 2014-03-18 2015-09-24 Actelion Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
KR20180053345A (ko) 2015-09-15 2018-05-21 이도르시아 파마슈티컬스 리미티드 결정질 형태
KR20190103507A (ko) 2018-02-12 2019-09-05 김강민 지하철 혼잡도 알림 시스템
WO2019139462A2 (ko) * 2019-02-21 2019-07-18 엘지전자 주식회사 하차 시점 알림 방법 및 사용자 단말
TW202100015A (zh) 2019-02-28 2021-01-01 瑞士商先正達農作物保護公司 具有含硫取代基之殺有害生物活性雜環衍生物
CN114681438B (zh) * 2022-05-17 2024-03-19 中国医学科学院基础医学研究所 二甲双胍及其它含胍化合物在逆转Gal-10结晶趋势并缓解相关疾病中应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE790679A (fr) 1971-11-03 1973-04-27 Ici Ltd Derives de l'indole
GB9125842D0 (en) 1991-12-04 1992-02-05 Ici Plc Heterocyclic derivatives
ES2237470T3 (es) * 1999-11-10 2005-08-01 Ortho-Mcneil Pharmaceutical, Inc. 2-aril-3-(heteroaril)-imidazo(1,2-alfa)pirimidinas sustituidas; y composiciones farmaceuticas y procedimientos asociados.
JP2001302667A (ja) 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
US6878522B2 (en) 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
EP1413306A1 (en) 2002-10-21 2004-04-28 Warner-Lambert Company LLC Tetrahydroquinoline derivatives as CRTH2 antagonists
PL377314A1 (pl) * 2002-12-20 2006-01-23 Amgen Inc. Modulatory astmy i zapaleń na tle alergicznym
PT1471057E (pt) 2003-04-25 2006-05-31 Actimis Pharmaceuticals Inc Derivados de acido pirimidinilacetico uteis para o tratamento de doencas mediadas por crth2

Similar Documents

Publication Publication Date Title
JP2007519659A5 (https=)
JP2019031560A5 (https=)
CN100537564C (zh) 代谢型谷氨酸受体-5的二芳基取代三唑调节剂
JP2004524301A5 (https=)
JP2010527985A5 (https=)
CN105120868A (zh) 组合治疗
JP2012505234A5 (https=)
JP2010527984A5 (https=)
JP2009543795A5 (https=)
JP2010516701A5 (https=)
EA037738B1 (ru) Кристаллические формы ингибиторов глутаминазы
JP2010526801A5 (https=)
US20060019970A1 (en) Methods and compositions for the treatment of neuroleptic and related disorders using ziprasidone metabolites
JP2009501745A5 (https=)
WO2016000568A1 (zh) 一种治疗痛风的化合物
JP2005538974A5 (https=)
JP2004521150A5 (https=)
CA2553704C (en) Substituted benzimidazoles and their use for inducing apoptosis
JP2005526138A5 (https=)
JP2010513489A5 (https=)
CN105745193B (zh) 抗真菌氧代二氢吡啶碳酰肼衍生物
CN104744493A (zh) 3-苯甲酰基-5,7-二苯基-5H-噻唑并[3,2-a]嘧啶类衍生物及其应用
JP2010514682A5 (https=)
AU2013366974B2 (en) Cinnamic acid amide derivative
CN104844628B (zh) 2H,6H‑嘧啶并[2,1‑b][1,3]噻嗪类衍生物及其应用